Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia

Lung Cancer. 2013 Oct;82(1):171-2. doi: 10.1016/j.lungcan.2013.07.004. Epub 2013 Aug 9.

Abstract

We report a patient with squamous cell carcinoma (SQCC) of the lung and a discoid-receptor-2 (DDR2) kinase domain mutation that responded to dasatinib treatment. Our case report is consistent with previous publications suggesting that DDR2 mutation may confer sensitivity to dasatinib.

Keywords: Chronic myelogenous leukemia; DDR2; Dasatinib; Driver mutations; Squamous-cell carcinoma; Targeted therapies.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Squamous Cell / diagnostic imaging*
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / genetics
  • DNA Mutational Analysis
  • Dasatinib
  • Discoidin Domain Receptors
  • Female
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnostic imaging*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Lung Neoplasms / diagnostic imaging*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Middle Aged
  • Mutation, Missense
  • Neoplasms, Multiple Primary / diagnostic imaging*
  • Neoplasms, Multiple Primary / drug therapy
  • Neoplasms, Multiple Primary / genetics
  • Pyrimidines / therapeutic use*
  • Radiography
  • Receptor Protein-Tyrosine Kinases / genetics*
  • Receptors, Mitogen / genetics*
  • Thiazoles / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Pyrimidines
  • Receptors, Mitogen
  • Thiazoles
  • Discoidin Domain Receptors
  • Receptor Protein-Tyrosine Kinases
  • Dasatinib